Meropenem Sun (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: achieves bacterial eradication in severe abdominal sepsis.
• Complicated urinary tract infections: clears resistant uropathogens causing pyelonephritis.
• Bacterial meningitis: penetrates the cerebrospinal fluid to treat meningitic pathogens.
• Skin and soft tissue infections: resolves deep or necrotizing infections.
• Sepsis: provides rapid bactericidal activity in systemic infection.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell death. Its high affinity for a broad range of PBPs confers activity against many Gram‑negative, Gram‑positive and anaerobic organisms, including many resistant strains.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Headache: transient cranial discomfort.
• Elevated liver enzymes: mild transaminase rise.
• Injection site pain: local discomfort during administration.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or high doses.
• Anaphylaxis: acute hypersensitivity reaction requiring emergency care.
• Clostridioides difficile infection: severe colitis due to gut flora disruption.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are essential when using Meropenem.

• Renal impairment: dose adjustment may be required and renal function should be monitored.
• Hepatic impairment: monitor liver function tests during prolonged therapy.
• Known carbapenem allergy: avoid use in patients with documented hypersensitivity.
• Pregnancy (Category B): weigh maternal benefits against potential fetal risk.
• Neonates and pediatric patients: dosing must be individualized based on weight and age.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Meropenem can alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
• Oral contraceptives: may decrease hormonal efficacy, leading to unintended pregnancy.
• Probenecid: can increase meropenem plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: combined nephrotoxic potential requires renal monitoring.
• Loop diuretics: may exacerbate renal dysfunction.
• Anticoagulants (e.g., warfarin): monitor INR for possible alterations in anticoagulant effect.
• Other antibiotics: assess for additive toxicity or antagonism.